New opportunities to optimize antithrombotic therapy for secondary stroke prevention

被引:4
作者
Kim, Anthony S. [1 ]
Easton, J. Donald [1 ]
机构
[1] UCSF, Dept Neurol, San Francisco, CA USA
关键词
Stroke prevention; secondary stroke prevention; antithrombotic; antiplatelet; clopidogrel; ticagrelor; aspirin; transient ischemic attack; MINOR STROKE; ASPIRIN; CLOPIDOGREL;
D O I
10.1177/1747493019828548
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Stroke symptoms can be unsettling, even when symptoms resolve, but focusing on stroke prevention can be empowering provided that effective interventions for appropriate patient populations are available. Current options include interventions for symptomatic carotid artery stenosis, anticoagulation for atrial fibrillation, high-dose statins, new oral anticoagulants, new developments in atrial fibrillation detection, and new therapeutics are in development. For antiplatelet therapy, aspirin monotherapy is effective but dual antiplatelet therapy with the combination of aspirin and clopidogrel increases hemorrhage risks over the long term that outweigh potential benefits. In the short term though, both the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials have shown a benefit of short-term dual-antiplatelet therapy, though the increased major hemorrhage risk seen in POINT could justify applying dual-antiplatelet therapy to just the first 21 days. Furthermore, since clopidogrel is a prodrug that must be metabolized to have antiplatelet activity, it is not surprising that the treatment effect in CHANCE was limited to patients who were not carriers of loss-of-function alleles for clopidogrel metabolism. Ticagrelor, an antiplatelet agent which failed to meet its primary endpoint as monotherapy compared to aspirin in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial, is currently being tested as combination therapy with aspirin compared to aspirin alone in Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES). These developments along with improvements to the infrastructure to perform rapid evaluations and to apply intensive secondary stroke prevention interventions hold continued promise for the future.
引用
收藏
页码:220 / 222
页数:3
相关论文
共 50 条
  • [31] Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke
    Tse, Dominic
    Hill, Michael D.
    Coutts, Shelagh B.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2019, 19 (06)
  • [32] Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke
    Pace, Wilson D.
    Earl, Ali
    Bryant, Casey
    Hansen, Cory
    US PHARMACIST, 2020, 45 (01) : HS8 - HS12
  • [33] Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke
    Dominic Tse
    Michael D. Hill
    Shelagh B. Coutts
    Current Neurology and Neuroscience Reports, 2019, 19
  • [34] Antithrombotic Therapy for Prevention of Various Thrombotic Diseases
    Goto, Shinya
    Tomita, Aiko
    DRUG DEVELOPMENT RESEARCH, 2013, 74 (08) : 568 - 574
  • [35] Dual Antiplatelet Therapy for the Acute Management and Long-term Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack, An Updated Review
    Chan, Bernard P. L.
    Wong, Lily Y. H.
    Tan, Benjamin Y. Q.
    Yeo, Leonard L. L.
    Venketasubramanian, Narayanaswamy
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2024, 11 (02)
  • [36] Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease
    Welsh, Robert C.
    Peterson, Eric D.
    De Caterina, Raffaele
    Bode, Christoph
    Gersh, Bernard
    Eikelboom, John W.
    AMERICAN HEART JOURNAL, 2019, 218 : 100 - 109
  • [37] The new Epoch of Antithrombotic Therapyin the Long-Term Prevention of a non-Cardioembolic Stroke
    Fonyakin, A., V
    Geraskina, L. A.
    KARDIOLOGIYA, 2020, 60 (12) : 97 - 103
  • [38] Use of Cilostazol for Secondary Stroke Prevention: An Old Dog with New Tricks?
    Ansara, Alexander J.
    Shiltz, Dane L.
    Slavens, Jennifer B.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (03) : 394 - 402
  • [39] Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease
    Lettino, Maddalena
    Leonardi, Sergio
    De Maria, Elia
    Halvorsen, Sigrun
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 : 61 - 70
  • [40] Hemorrhagic transformation and stroke recurrence in children with cardiac disease receiving antithrombotic therapy for secondary stroke prevention
    Pulcine, Elizabeth
    Seed, Mike
    Brandao, Leonardo R.
    Slim, Mahmoud
    Palasamudram, Sunitha
    Shroff, Manohar
    Moharir, Mahendranath
    deVeber, Gabrielle
    Dlamini, Nomazulu
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (10) : 2428 - 2439